(HealthDay)—For patients with type 2 diabetes (T2D), with or without
Read moreSGLT2 inhibitors may cut risk for heart failure hospitalization
Home »
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
NEW YORK–(BUSINESS WIRE) November 23, 2020 — Pfizer Inc. (NYSE:
Read morePCSK9 inhibitors have unexpected anti-inflammatory effects
PCSK9 inhibition is a new therapeutic strategy for atherosclerosis which
Read more